 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 by AFP Staff Writers Washington (AFP) May 11, 2021
US biotech firm Novavax on Monday said it had delayed plans to seek authorization for its Covid vaccine candidate, a setback for developing countries hoping the injection would soon be available. The company now hopes to file for authorization in the US and Europe in the third quarter of 2021, it said in a statement, sending shares tumbling 12 percent. Novavax's vaccine is key to the Covax program, which was set up to try to ensure poor countries have equitable access to vaccines to combat the coronavirus pandemic. Its NVX-CoV2373 vaccine candidate demonstrated 100 percent protection against severe disease in a Phase 3 clinical trial in Britain, with 89.7 percent efficacy against any form of the disease. It uses a piece of the SARS-CoV-2 virus called the spike protein, which the company mass-produces inside insect cells, and can be stored at regular refrigeration temperatures. Novavax also said Monday it had had positive results from preclinical studies of a shot combining its influenza and Covid vaccine candidates. The company said a study, which will now undergo peer review, showed that the shot produced strong levels of antibodies against both diseases in ferrets and hamsters. "Despite low rates during the Covid-19 pandemic, influenza remains a significant risk to global public health and the need for versatile, more effective vaccines is as important as ever, including against the flu," said Gregory Glenn, the company's president of R&D. The new vaccine combines NanoFlu and NVX-CoV2373. Hamsters that were vaccinated and then deliberately infected with the coronavirus retained their body weight compared to those that received a placebo. Lung samples taken from the immunized animals after they were put down showed they were Covid-free.
Novavax developing combination flu, Covid vaccine The company said a study, which it has posted to a preprint server and will now undergo peer review, showed that the shot produced strong levels of antibodies against both diseases in ferrets and hamsters. "Despite low rates during the Covid-19 pandemic, influenza remains a significant risk to global public health and the need for versatile, more effective vaccines is as important as ever, including against the flu," said Gregory Glenn, the company's president of R&D. The new vaccine combines NanoFlu and NVX-CoV2373, which are separately in late-stage human trials. Neither have yet been approved. Hamsters that were vaccinated and then deliberately infected with the coronavirus retained their body weight compared to those that received a placebo. Lung samples taken from the immunized animals after they were put down showed they were Covid-free. NVX-CoV2373, the company's Covid vaccine candidate, demonstrated 100 percent protection against severe disease in a Phase 3 clinical trial in the United Kingdom, with 89.7 percent efficacy against any form of disease. NVX-CoV2373 uses a piece of the SARS-CoV-2 virus called the spike protein, which the company mass produces inside insect cells. It packages the spike inside nanoparticles and delivers these to the immune system, which trains the host in case they encounter the real virus. The vaccine contains a substance called an adjuvant to deliver a stronger signal to the immune system to respond. NanoFlu is based on similar principles but instead of the spike protein, it presents hemagglutinin -- a protein on the outside of the influenza virus -- to the immune system.
Dust storms and valley fever in the American West Greenbelt MD (SPX) May 07, 2021 Valley fever is a dangerous threat to human health - and cases are on the rise in the arid southwestern United States, as wind from increasing dust storms can transport the fungal spores that cause the disease. Valley fever is caused by the Coccidioides fungus, which grows in dirt and fields and can cause fever, rash and coughing. Using NASA research and satellite data, the World Meteorological Organization is refining its Sand and Dust Storm Warning Advisory and Assessment System to help forecast where ... read more
|
|||||||||||||
|
|
| The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |
del.icio.us
Digg
Reddit
Google
